Alnylam Pharmaceuticals, Inc. (LON:0HD2)

Market Cap	44.42B
Revenue (ttm)	2.39B
Net Income (ttm)	32.41M
Shares Out	n/a
EPS (ttm)	0.25
PE Ratio	1,370.63
Forward PE	50.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131
Average Volume	507
Open	435.70
Previous Close	437.87
Day's Range	432.37 - 439.40
52-Week Range	209.75 - 500.21
Beta	n/a
RSI	41.49
Earnings Date	Oct 30, 2025

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 2,230
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HD2

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD